Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) Debt to Equity (2019 - 2022)

BioScience Health Innovations has reported Debt to Equity over the past 4 years, most recently at $0.38 for Q2 2022.

  • Quarterly Debt to Equity rose 119.64% to $0.38 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $0.38 through May 2022, up 119.64% year-over-year, with the annual reading at -$1.36 for FY2021, 323.55% down from the prior year.
  • Debt to Equity was $0.38 for Q2 2022 at BioScience Health Innovations, up from $0.24 in the prior quarter.
  • Over five years, Debt to Equity peaked at $3.22 in Q4 2019 and troughed at -$239.04 in Q1 2020.
  • The 4-year median for Debt to Equity is -$0.08 (2020), against an average of -$23.89.
  • Year-over-year, Debt to Equity crashed 369.01% in 2021 and then skyrocketed 119.64% in 2022.
  • A 4-year view of Debt to Equity shows it stood at $3.22 in 2019, then plummeted by 39.48% to $1.95 in 2020, then tumbled by 87.76% to $0.24 in 2021, then soared by 57.49% to $0.38 in 2022.
  • Per Business Quant, the three most recent readings for BHIC's Debt to Equity are $0.38 (Q2 2022), $0.24 (Q4 2021), and -$1.36 (Q3 2021).